keyword
MENU ▼
Read by QxMD icon Read
search

Non small cell lung cancer

keyword
https://www.readbyqxmd.com/read/28634676/evaluation-of-the-psychometric-properties-of-the-eortc-chemotherapy-induced-peripheral-neuropathy-questionnaire-qlq-cipn20
#1
Jacobien M Kieffer, Tjeerd J Postma, Lonneke van de Poll-Franse, Floortje Mols, Jan J Heimans, Guido Cavaletti, Neil K Aaronson
PURPOSE: To investigate the scale structure and psychometrics of the EORTC chemotherapy-induced peripheral neuropathy module (QLQ-CIPN20). METHODS: Using confirmatory factor analyses (CFA), we tested two hypothesized scale structure models of the QLQ-CIPN20 in 473 patients with non-small cell lung cancer, 281 patients with heterogeneous cancer diagnoses, and 500 patients with colorectal cancer. We also modeled the two hypothesized models as bi-factor models. These included a general factor, in addition to the specific domain factors...
June 20, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28634225/homeobox-transcription-factor-nkx2-1-promotes-cyclin-d1-transcription-in-lung-adenocarcinomas
#2
Masanori Harada, Satoshi Sakai, Tatsuya Ohhata, Kyoko Kitagawa, Masashi Mikamo, Koji Nishimoto, Chiharu Uchida, Hiroyuki Niida, Yojiro Kotake, Haruhiko Sugimura, Takafumi Suda, Masatoshi Kitagawa
The known oncogene cyclin D1 (CCND1) participates in progression of the cell cycle from G1 to S phase. Expression of cyclin D1 is frequently promoted in multiple human cancers including non-small cell lung cancer (NSCLC). However, a relationship between cyclin D1 expression and the prognosis of NSCLC has not been confirmed. NKX2-1 is a homeobox transcription factor involved in pulmonary development as a differentiation-promoting factor. In NSCLC, it acts as a metastasis suppressor and correlates with a good prognosis...
June 20, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28633480/a-prospective-examination-of-circulating-tumor-cell-profiles-in-non-small-cell-lung-cancer-molecular-subgroups
#3
C R Lindsay, V Faugeroux, S Michiels, E Pailler, F Facchinetti, D Ou, M V Bluthgen, C Pannet, M Ngo-Camus, G Bescher, C Caramella, F Billiot, J Remon, D Planchard, J-C Soria, B Besse, F Farace
Background: We report the first study examining the clinical, numerical and biological properties of circulating tumor cells (CTCs) according to molecular subtypes of non-small cell lung cancer (NSCLC). Patients and Methods: 125 patients with treatment-naïve stage IIIb-IV NSCLC were prospectively recruited for CellSearch analysis. Anti-vimentin antibody was included for examination of CTCs to assess their mesenchymal character. Associations of total CTCs and vimentin-positive (vim +) CTCs with clinical characteristics, tumor genotype and survival were assessed...
June 19, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633222/endosonographic-mediastinal-lymph-node-staging-in-non-small-cell-lung-cancer-how-i-teach-it
#4
EDITORIAL
Ricardo L Oliveira, Moishe Liberman
No abstract text is available yet for this article.
July 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28632731/cd47-overexpression-is-associated-with-decreased-neutrophil-apoptosis-phagocytosis-and-poor-prognosis-in-non-small-cell-lung-cancer-patients
#5
Lourdes Barrera, Edgar Montes-Servín, Juan-Manuel Hernandez-Martinez, María de Los Ángeles García-Vicente, Elizabeth Montes-Servín, Marytere Herrera-Martínez, José C Crispín, José Rafael Borbolla-Escoboza, Oscar Arrieta
BACKGROUND: Non-small-cell lung cancer (NSCLC) patients often exhibit neutrophilia, which has been associated with poor clinical outcomes. However, the mechanisms that lead to neutrophilia have not been fully established. CD47 is an antiphagocytic molecule that promotes neutrophil recruitment. METHODS: Blood was collected from 50 treatment-naive patients with advanced NSCLC and from 25 healthy subjects. The frequency of CD66b(+) cells and the expression of CD47 were determined by flow cytometry...
June 20, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28631573/effects-of-mir-1236-3p-and-mir-370-5p-on-activation-of-p21-in-various-tumors-and-its-inhibition-on-the-growth-of-lung-cancer-cells
#6
Chuanchang Li, Qiangqiang Ge, Jiaxuan Liu, Qingsong Zhang, Chenghe Wang, Kai Cui, Zhong Chen
The mechanism of dsRNA-induced gene activation (RNAa) is being gradually unveiled. The plentiful evidence that it existed in mammalian species other than human demonstrated that dsRNA-mediated RNAa is a conservative phenomenon. Simultaneously, accumulating evidence suggested that microRNAs could activate gene expression by targeting promoter. Nevertheless, it is ambiguous whether microRNA-induced gene activation in different human cells is a common phenomenon. The study we performed verified that miR-1236-3p (miR-1236) and miR-370-5p can activate p21 expression in bladder cancer (BCa) T24, EJ cells, and non-small-cell lung carcinoma A549 cells, while in hepatocellular HepG2 cells both microRNAs cannot effectively induce the expression of P21(WAF1/CIP1) (p21)...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28631567/microrna-1285-5p-influences-the-proliferation-and-metastasis-of-non-small-cell-lung-carcinoma-cells-via-downregulating-cdh1-and-smad4
#7
Shixia Zhou, Zhongmian Zhang, Pengyuan Zheng, Wenchao Zhao, Na Han
Abnormal expression of microRNAs has been reported to regulate gene expression and cancer cell growth, invasion, and migration. Recently, upregulation of hsa-miR-1285 was demonstrated in bronchoalveolar lavage fluid samples from patients with lung cancer and downregulation in plasma level of stage-I lung cancer patients. However, the function and the underlying mechanism of miR-1285 in non-small-cell lung carcinoma have not been elucidated. In this study, we found that miR-1285-5p, the mature form of miR-1285, was significantly upregulated in human non-small-cell lung carcinoma cell lines A549 and SK-MES-1...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28631556/kruppel-like-factor-4-inhibits-non-small-cell-lung-cancer-cell-growth-and-aggressiveness-by-stimulating-transforming-growth-factor-%C3%AE-1-meidated-erk-jnk-nf-%C3%AE%C2%BAb-signaling-pathways
#8
Renzhi Yu, Lei Han, Xin Ni, Minghuan Wang, Ping Xue, Li Zhang, Mei Yuan
Non-small cell lung cancer is one of the most common epithelial tumors that cause the most common cancer-related mortality due to invasive ability. Research has found that Kruppel-like factor 4, a zinc-finger transcription factor, plays a critical role in the tumor evolution and progression. However, the molecular signal pathways mediated by Kruppel-like factor 4 in the progression of non-small cell lung cancer cells have not been well understood yet. In this study, we investigated the possible role and potential mechanism of Kruppel-like factor 4 in growth and aggressiveness of non-small cell lung cancer cells...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28631135/long-term-clinical-benefit-from-salvage-egfr-tyrosine-kinase-inhibitors-in-advanced-non-small-cell-lung-cancer-patients-with-egfr-wild-type-tumors
#9
F Koinis, A Voutsina, A Kalikaki, A Koutsopoulos, E Lagoudaki, E Tsakalaki, E K Dermitzaki, E Kontopodis, A G Pallis, V Georgoulias, A Kotsakis
BACKGROUND: Erlotinib has been approved for the management of NSCLC patients after failure of the first or subsequent line of chemotherapy. Although the efficacy of erlotinib is clearly associated with the presence of EGFR mutations, there is a subset of patients with EGFR wild-type (EGFRwt) tumors who impressively respond. PATIENTS AND METHODS: Patients with EGFRwt NSCLC who received salvage (≥2nd line) treatment with erlotinib for a prolonged period (>6 months), were sought from the database of the Hellenic Oncology Research Group...
June 19, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28631096/a-case-of-nivolumab-related-cholangitis-and-literature-review-how-to-look-for-the-right-tools-for-a-correct-diagnosis-of-this-rare-immune-related-adverse-event
#10
Francesco Gelsomino, Giovanni Vitale, Andrea Ardizzoni
Anti-programmed cell death-1 (PD-1) monoclonal antibodies, such as nivolumab, used for the treatment of several tumors, can trigger effector T-cells against tumor- and self-antigens, leading to the occurrence of different immune-related adverse events. Among them, liver injuries are rare and usually transient. To date, only four cases of immune-related cholangitis in non-small cell lung cancer (NSCLC) patients have been described during nivolumab treatment. Here, we describe laboratory tests, imaging and liver biopsy features that confirm this diagnosis as opposed to other forms of autoimmune liver disease; nevertheless, we also provide evidence of the presence of different clinical-pathological patterns of immune-related cholangitis...
June 20, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28630876/a-dosimetric-comparison-of-dose-escalation-with-simultaneous-integrated-boost-for-locally-advanced-non-small-cell-lung-cancer
#11
Wenjuan Yang, Biao Zeng, Yanfang Qiu, Jianfeng Tan, Shilei Xu, Yilong Cai, Yujuan Zhou, Zhigang Liu, Junming Luo, Hui Wang
BACKGROUND: Many studies have demonstrated that a higher radiotherapy dose is associated with improved outcomes in non-small-cell lung cancer (NSCLC). We performed a dosimetric planning study to assess the dosimetric feasibility of intensity-modulated radiation therapy (IMRT) with a simultaneous integrated boost (SIB) in locally advanced NSCLC. METHODS: We enrolled twenty patients. Five different dose plans were generated for each patient. All plans were prescribed a dose of 60 Gy to the planning tumor volume (PTV)...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28630494/structure-guided-design-of-c4-alkyl-1-4-dihydro-2h-pyrimido-4-5-d-1-3-oxazin-2-ones-as-potent-and-mutant-selective-epidermal-growth-factor-receptor-egfr-l858r-t790m-inhibitors
#12
Yongjia Hao, Jiankun Lyu, Rong Qu, Deheng Sun, Zhenjiang Zhao, Zhuo Chen, Jian Ding, Hua Xie, Yufang Xu, Honglin Li
Epidermal growth factor receptor (EGFR) T790M acquired drug-resistance mutation has become a major clinical challenge for the therapy of non-small cell lung cancer. Here, we applied a structure-guided approach on the basis of the previous reported EGFR inhibitor (compound 9), and designed a series of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-one derivatives as novel mutant-selective EGFR inhibitors. Finally, the most representative compound 20a was identified, which showed high selectivity at both enzymatic and cellular levels against EGFR(L858R/T790M) (H1975 cell lines) over EGFR(WT) (A431 cell lines)...
June 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28629896/randomized-phase-ii-study-of-preoperative-chemoradiotherapy-panitumumab-followed-by-consolidation-chemotherapy-in-potentially-operable-locally-advanced-stage-iiia-n2-non-small-cell-lung-cancer-nrg-oncology-rtog-0839
#13
Martin J Edelman, Chen Hu, Quynh-Thu Le, Jessica S Donington, Warren D D'Souza, Adam P Dicker, Billy W Loo, Elizabeth M Gore, Gregory M M Videtic, Nathaniel R Evans, Joseph W Leach, Maximilian Diehn, Steven J Feigenberg, Yuhchyau Chen, Rebecca Paulus, Jeffrey D Bradley
INTRODUCTION: Multimodality therapy has curative potential in locally advanced non-small cell lung cancer (LASCLC). Mediastinal nodal sterilization (MNS) after induction chemoradiotherapy (CRT) can serve as an intermediate marker for efficacy. NRG Oncology RTOG 0229 demonstrated the feasibility and efficacy of combining full dose radiation (61.2Gy) with chemotherapy followed by resection and chemotherapy. Based upon that experience and evidence that epidermal growth factor receptor (EGFR) antibodies are radiosensitizing, we explored adding panitumumab to CRT followed by resection and consolidation chemotherapy in LANSCLC with a primary endpoint of MNS...
June 16, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28629433/smoking-and-timing-of-cessation-on-postoperative-pulmonary-complications-after-curative-intent-lung-cancer-surgery
#14
Sebastian T Lugg, Theofano Tikka, Paula J Agostini, Amy Kerr, Kerry Adams, Maninder S Kalkat, Richard S Steyn, Pala B Rajesh, Ehab Bishay, David R Thickett, Babu Naidu
BACKGROUND: Smoking is a risk factor for postoperative pulmonary complications (PPC) following non-small cell lung cancer (NSCLC) surgery. The optimal timing for preoperative smoking cessation has not been identified. Our study aimed to observe the impact of preoperative smoking cessation on PPC incidence and other postoperative outcomes including long-term survival. METHODS: A prospective study included consecutive patients following resection for NSCLC in a regional thoracic centre over a 4-year period (2010-2014)...
June 19, 2017: Journal of Cardiothoracic Surgery
https://www.readbyqxmd.com/read/28629431/microrna-330-3p-promotes-cell-invasion-and-metastasis-in-non-small-cell-lung-cancer-through-gria3-by-activating-mapk-erk-signaling-pathway
#15
Chun-Hua Wei, Gang Wu, Qian Cai, Xi-Can Gao, Fan Tong, Rui Zhou, Rui-Guang Zhang, Ji-Hua Dong, Yu Hu, Xiao-Rong Dong
BACKGROUND: Brain metastasis (BM) is associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). Recent studies demonstrated that microRNA-330-3p (miR-330-3p) was involved in NSCLC brain metastasis (BM). However, the exact parts played by miR-330-3p in BM of NSCLC remain unknown. Discovery and development of biomarkers and elucidation of the mechanism underlying BM in NSCLC is critical for effective prophylactic interventions. Here, we evaluated the expression and biological effects of miR-330-3p in NSCLC cells and explored the underlying mechanism of miR-330-3p in promoting cell migration and invasion in NSCLC...
June 19, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28629197/reply-to-the-letter-to-the-editor-by-c-nicolazzo-et-al-circulating-cell-free-dna-and-circulating-tumor-cells-as-prognostic-and-predictive-biomarkers-in-advanced-non-small-cell-lung-cancer-patients-treated-with-first-line-chemotherapy
#16
https://www.readbyqxmd.com/read/28628916/comprehensive-biomarker-analyses-in-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-prospectively-treated-with-the-polo-like-kinase-1-inhibitor-bi2536
#17
Frank Breitenbuecher, Joachim von Pawel, Martin Sebastian, Cornelius Kortsik, Saskia Ting, Stefan Kasper, Jeremias Wohlschläger, Karl Worm, Alicia Morresi-Hauf, Arno Schad, Daniela Westerwick, Beatrice Wehler, Martin Werner, Gerd Munzert, Birgit Gaschler-Markefski, Kurt W Schmid, Martin Schuler
No abstract text is available yet for this article.
June 20, 2017: Oncology Research and Treatment
https://www.readbyqxmd.com/read/28627833/comparison-of-the-analytical-performance-between-cobas-egfr-assay-and-pcr-clamp-method-in-the-detection-of-egfr-mutations-in-japanese-non-small-cell-lung-cancer-patients
#18
Tomohiko Ai, Maiko Yuri, Yoko Tabe, Atsushi Kakimoto, Soji Morishita, Koji Tsuchiya, Kazuya Takamochi, Yuzo Kodama, Fumiyuki Takahashi, Misawa Shigeki, Takashi Horii, Kenji Suzuki, Kazuhisa Takahashi, Takashi Miida, Akimichi Ohsaka
BACKGROUND: EGFR, a tyrosine-kinase, plays an important role in the progression of lung cancer. Since genetic abnormality of EGFR alters the effects of tyrosine-kinase inhibitors targeting EGFR, molecular analyses of EGFR have recently gained more attention in the treatment of lung cancer. However, several different techniques are available and which method is superior has not been determined. In this study, we compared two recently developed PCR-based techniques, PCR-clamp method and cobas EGFR assay...
May 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28627767/clinical-significance-of-post-progression-survival-in-lung-cancer
#19
REVIEW
Hisao Imai, Kyoichi Kaira, Koichi Minato
Progression-free survival (PFS) and overall survival (OS) are two common endpoints in cancer trials. OS is usually preferred, because it is reliable, precise, meaningful, and can easily be documented. However, subsequent lines of therapy might confound the effects of first-line treatment on OS. Whether PFS or OS is the more appropriate endpoint in clinical trials of metastatic cancer remains controversial. Previous reports on lung cancer have shown that an increase in PFS does not necessarily result in an increase in OS; however, post-progression survival (PPS) is strongly associated with OS after early-line treatment...
June 19, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28627678/bevacizumab-counteracts-vegf-dependent-resistance-to-erlotinib-in-an-egfr-mutated-nsclc-xenograft-model
#20
Chinami Masuda, Mieko Yanagisawa, Keigo Yorozu, Mitsue Kurasawa, Koh Furugaki, Nobuyuki Ishikura, Toshiki Iwai, Masamichi Sugimoto, Kaname Yamamoto
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating EGFR mutations (EGFR Mut+). However, almost all tumors eventually develop resistance to erlotinib. Recently, the Phase II JO25567 study reported significant prolongation of progression-free survival (PFS) by erlotinib plus bevacizumab combination compared with erlotinib in EGFR Mut+ NSCLC. Herein, we established a preclinical model which became refractory to erlotinib after long-term administration and elucidated the mode of action of this combination...
June 8, 2017: International Journal of Oncology
keyword
keyword
8878
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"